Jonathan O. Cullis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan O. Cullis has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
C. Mathews
Department of Haematology, Salisbury District Hospital, Salisbury SP2 8BJ, UK
1 shared publicationCharles Alderman
Department of Haematology Salisbury NHS Foundation Trust Salisbury Wiltshire UK
1 shared publicationEmily Roberts
Department of Haematology, Salisbury District Hospital, Salisbury, Wiltshire, UK
1 shared publicationJonathan Corlett
ENT Salisbury NHS Foundation Trust Salisbury Wiltshire UK
1 shared publicationKrishnappa C. Madhusudhana
Eye Unit, Southampton General Hospital, Southampton, Hampshire, UK
1 shared publicationMarianna Koperdanova
Salisbury District Hospital, Salisbury SP2 8BJ, UK
1 shared publication
Latest Publications
- Open Access
- 14 May 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (4) , 547-548
The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab
- 14 May 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (4) , 547-548
Open AccessThe treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab
- Open Access
- 1 April 2013
- Published by Elsevier in Clinical Medicine
- Vol. 13 (2) , 193-196
Anaemia of chronic disease
- 1 April 2013
- Published by Elsevier in Clinical Medicine
- Vol. 13 (2) , 193-196
Open AccessAnaemia of chronic disease
- 25 May 2011
- Published by Wiley in British Journal of Haematology
- Vol. 154 (3) , 289-300
Diagnosis and management of anaemia of chronic disease: current status
Summary: Anaemia of chronic disease is the second most common form of anaemia worldwide, and is seen in a variety of inflammatory, infective and malignant diseases. Functional iron deficiency is fundamental to the pathogenesis of the anaemia, and the polypeptide, hepcidin, plays a key role. Diagnosis may be difficult, but new automated red cell indices, algorithms for detection of functional iron deficiency, and assays for hepcidin levels are being developed. Management of the causative disease process will usually improve haemoglobin levels, but where this is not possible, erythropoietic stimulating agents are often used, although there are still concerns about potential adverse effects, especially thromboembolism. There is increasing evidence that supplemental iron given parenterally can safely overcome the functional iron deficiency. Inhibitors of hepcidin, and various inflammatory modulators show promise for the future.
- 25 May 2011
- Published by Wiley in British Journal of Haematology
- Vol. 154 (3) , 289-300
Diagnosis and management of anaemia of chronic disease: current status
Summary: Anaemia of chronic disease is the second most common form of anaemia worldwide, and is seen in a variety of inflammatory, infective and malignant diseases. Functional iron deficiency is fundamental to the pathogenesis of the anaemia, and the polypeptide, hepcidin, plays a key role. Diagnosis may be difficult, but new automated red cell indices, algorithms for detection of functional iron deficiency, and assays for hepcidin levels are being developed. Management of the causative disease process will usually improve haemoglobin levels, but where this is not possible, erythropoietic stimulating agents are often used, although there are still concerns about potential adverse effects, especially thromboembolism. There is increasing evidence that supplemental iron given parenterally can safely overcome the functional iron deficiency. Inhibitors of hepcidin, and various inflammatory modulators show promise for the future.
- 1 August 2008
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 30 (4) , 331-333
Cost-effectiveness of rituximab in refractory cold agglutinin disease
Cold haemagglutinin disease (CHAD) is an uncommon condition frequently associated with B-cell lymphoproliferative disorders and is refractory to conventional treatments used in autoimmune haemolytic anaemia. Rituximab has been used in this condition with favourable and lasting responses. Cost has been a major limitation to its use in such indication. We present cost-effectiveness analysis of the use of rituximab in two patients with CHAD. Rituximab successfully controlled haemolysis in both cases of CHAD and was found to be cost-effective through reducing transfusion needs.
- 1 August 2008
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 30 (4) , 331-333
Cost-effectiveness of rituximab in refractory cold agglutinin disease
Cold haemagglutinin disease (CHAD) is an uncommon condition frequently associated with B-cell lymphoproliferative disorders and is refractory to conventional treatments used in autoimmune haemolytic anaemia. Rituximab has been used in this condition with favourable and lasting responses. Cost has been a major limitation to its use in such indication. We present cost-effectiveness analysis of the use of rituximab in two patients with CHAD. Rituximab successfully controlled haemolysis in both cases of CHAD and was found to be cost-effective through reducing transfusion needs.
- 27 April 2006
- Published by Wiley in British Journal of Haematology
- Vol. 133 (5) , 456
Blindness due to angioid streaks in congenital dyserythropoietic anaemia type I
- 27 April 2006
- Published by Wiley in British Journal of Haematology
- Vol. 133 (5) , 456
Blindness due to angioid streaks in congenital dyserythropoietic anaemia type I